India draws lessons from polio eradication initiative
- India draws lessons from polio eradication initiative
India draws lessons from polio eradication initiative
11 April 2022
The efforts to stop polio promise to prevent innumerable children from lifelong paralysis. Credit: Gavi/India/Manpreet Romana.
The programme to eradicate polio shows that mass immunisation is possible in India
The programme to eradicate polio shows that mass immunisation is possible in India.
By Agnee Ghosh.
IFFIm impact: Polio
IFFIm disbursed a total of US$ 260 million to Gavi for polio programmes from 2006 to June 2022, including polio eradication and the groundbreaking inactivated polio vaccine (IPV).
The last case of polio in India was reported in Howrah, West Bengal on 13 January 2011. Since then, India has been free of the disease, officially receiving polio-free certification from the World Health Organization on 27 March 2014.
“The absence of evidence is not evidence of absence. COVID-19 has caused a lot of delays in vaccination, so there is the anxiety of waiting and hoping there are no polio outbreaks in the country.”
The poliovirus, which causes flaccid paralysis in the central nervous system, has a long and tumultuous history in India, with country-wide immunisation initiatives and long-running battles with vaccine hesitancy.
India launched the National Immunisation Programme in 1978, later renamed the Universal Immunisation Programme in 1985. The programme introduced the BCG vaccine for tuberculosis, the oral polio vaccine, the diphtheria, pertussis (whooping cough), and tetanus (DPT) vaccine and the vaccine against typhoid-paratyphoid.
India launched an aggressive polio immunisation campaign, including using celebrities to promote the programme and running advertisements in print media and on radio to encourage people to get the vaccine.
A nationwide network of health professionals worked together to keep an eye out for outbreaks of disease under the aegis of the initiative. To ensure that the target of 172 million children was met, almost two million health workers worked from a network of more than 5,000 stations, visiting millions of homes to administer vaccinations.
Although there have been no official cases of polio in India since 2011, epidemiologists are cautious about India’s polio-free status.
Jayaprakash Muliyil, an Indian epidemiologist and chairperson of the Scientific Advisory Committee of the National Institute of Epidemiology, says, “The absence of evidence is not evidence of absence. COVID-19 has caused a lot of delays in vaccination, so there is the anxiety of waiting and hoping there are no polio outbreaks in the country.”
COVID-19 has disrupted other vaccination programmes in the country and there is concern that other diseases have gone unreported during the pandemic. Nonetheless, the polio campaigns provide valuable insights into the country’s large-scale immunisation programmes’ challenges and successes.
The success of India’s polio eradication programme shows that the country is capable of large-scale immunisation. However, it is recognised that the COVID-19 vaccine is significantly different from the polio vaccine.
K. Srinath Reddy, the president of the Public Health Foundation of India, says, “A respiratory virus like COVID-19 can spread far faster and in a much shorter time than polio, which is an enterovirus.”
He notes that the COVID-19 vaccine is an injectable that cannot be done by volunteers, unlike the polio vaccine.
“The primary healthcare infrastructure is very critical in our fight against the COVID-19 pandemic. Primary healthcare can deal with the early detection of symptoms by households, ensure isolation, find the people who are getting sicker and need to be transferred to hospital, deal with vaccine hesitancy and vaccine delivery, provide in-home care for long COVID, etc,” says Dr Reddy.
Primary healthcare teams like ASHAs and Anganwadi workers have done remarkably well in India’s fight to eradicate polio in the country, and Dr Reddy believes that their engagement in the fight against COVID-19 is critical. This is evident in the lack of a community health worker scheme in the urban areas which initially bore the brunt of the pandemic.
Dr Alex Joseph, an associate professor of epidemiology at SRM Institute of Science and Technology, says, “COVID-19 vaccines have a short life span and must be used immediately, which is not the case in the oral polio vaccine. Also, each person receiving the dose must be observed for some time, which is challenging when you’re conducting a country-wide vaccination campaign.”
According to Dr Joseph, polio was not taken seriously in the early years, but aggressive campaigning to dispel polio vaccination misconceptions was helpful in overcoming vaccine hesitancy.
Despite the differences between the campaign for COVID-19 and polio, the principles of immunisation have been shaped by the earlier campaign against polio in India. The lessons from the fight against polio show how much the country relies on the primary healthcare infrastructure and how important it is to remobilise community healthcare workers.
This article is republished from VaccinesWork under a Creative Commons license. Read the original article.
Safe, effective vaccines have reduced cases of polio by an astounding 99.9% since 1988, yet polio is still endemic in two countries. That’s why reaching a polio-free world through immunisation is a priority for Gavi and IFFIm. Thanks to vaccine bonds that raise immediate money on capital markets backed by donor pledges, IFFIm disbursed US$ 260 million to Gavi for polio programmes from 2006 to June 2022, which includes US$ 18.3 million for the groundbreaking inactivated polio vaccine (IPV).
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.